Pneumatic limb compression: A free lunch?  by Porter, John M.
As the old adage reminds us, beware of some-
thing too good to be true: it probably is. The notion
of obtaining permanent circulatory benefits in an
ischemic limb by temporary intermittent pneumatic
compression has been hovering around the edges of
vascular practice for decades. The concept reemerged
in recent years and now has a patina of scientific
respectability by the article by Delis and associates in
this issue of the Journal of Vascular Surgery.
I have historically dismissed this concept as non-
sense: A quest for a perpetual motion machine, in fact,
a free lunch. Long experience has taught that one
rarely gets something for nothing, and that is exactly
what appears to be happening here. What is going on?
Any consideration of a revolutionary proposal such
as permanent arterial circulatory improvement result-
ing from intermittent pneumatic limb compression
with persistence of benefits long after cessation of
compression requires consideration of two issues: is it
real, and how does it work. First, is it real. Prior anec-
dotal publications have suggested prolonged clinical
benefits, but in the absence of persuasive data they
were easily dismissed as wishful thinking on the part of
gullible authors. Now we have a proper scientific study
that cannot be so easily dismissed. The presented evi-
dence is indeed persuasive. In fact, the walking benefit
experienced by these patients with claudication far
exceeds that described for the two drugs currently
approved by the Food and Drug Administration for
use in intermittent claudication: pentoxifylline and
cilostazol. Of course, these patients were carefully
selected. They all had claudication only, patent iliac
arteries with superficial femoral artery occlusion, and
perhaps most important, a patent popliteal artery.
Interestingly, almost none of the patients had diabetes,
a population far different from our usual patients with
claudication. Nonetheless, the improvement in walk-
ing distance was indeed impressive. The improvement
in ankle/brachial index and popliteal artery blood flow
appears significant, although less impressive than the
dramatic improvement in walking distance. A small
concern here is that the control group experienced no
improvement. In almost every drug study of claudica-
tion, a noticeable improvement in the control/place-
bo group has been noted (with the exception of
cilostazol) presumably because of the learning that
occurs with repeated treadmill walking. I have always
had a built-in bias against studies that show no con-
trol/placebo improvement.
If we accept for the moment that these investiga-
tors have indeed observed a very important effect,
what could possibly be the cause of the observed
benefit? From the outset I reject a simple mechanical
explanation. The laws of physics, especially conserva-
tion of energy, suggest to me that the circulatory
deficiency during compression would only be bal-
anced by the enhanced flow during relaxation inci-
dent to venous emptying and refilling. Clearly there
must be some other explanation. These authors sug-
gest release of beneficial substances by the arterial
(and venous?) endothelium. Perhaps nitric oxide or
some other friendly nostrum may be involved, or per-
haps suspension of the veno-arteriolar reflex by
venous pressure reduction may be the important
mechanism. Presently we clearly do not know.
Anecdotes have been accumulating long enough.
The trial described in the study by Delis and associ-
ates is a step in the right direction; however, he had
a control group but not a placebo group, his patients
were carefully selected, and the number of patients
was small. The time has clearly come for a multicen-
ter, randomized trial. I suggest a proper placebo
group that has the foot pneumatic device applied for
the same number of hours per day as the treatment
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group, but with no pneumatic inflation. Perhaps
some sort of vibration could be added to the limbs of
the placebo group to simulate active treatment.
I do not know how well the device is tolerated,
but the patient compliance reported by Dr Delis was
a remarkable 86%. If this device proves to be both
effective and well tolerated, this could indeed repre-
sent a remarkable advance in our treatment of clau-
dication. Patients could have the pneumatic device
applied in the evening or even during sleep and
expect more than 100% improvement in walking dis-
tance, with the improvement maintained for months
after cessation of treatment. Presently we have no
idea of the actual duration of benefits, if any, and the
issue of reapplication of active treatment after 4 to 6
months of nonuse has not been addressed.
Please do not misunderstand my position. I am
assuredly no enthusiast for this treatment, a position
I clearly expressed previously.1 The whole thing still
intuitively strikes me as a futile quest for a free lunch.
However, based on to the evidence presented in the
article by Delis and associates, it is fair to say that my
attitude has changed from “ridiculous” to “maybe.”
It will behoove all of us to keep a careful, but criti-
cal, eye on this device. Who knows . . . it might
work.
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